{"id":"https://openalex.org/W1998767099","doi":"https://doi.org/10.1097/yic.0b013e3282f424c2","title":"Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor","display_name":"Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor","alternate_titles":[],"publication_year":2008,"publication_date":"2008-05-01","ids":{"openalex":"https://openalex.org/W1998767099","doi":"https://doi.org/10.1097/yic.0b013e3282f424c2","mag":"1998767099","pmid":"https://pubmed.ncbi.nlm.nih.gov/18408525"},"language":"en","primary_location":{"id":"doi:10.1097/yic.0b013e3282f424c2","doi":"https://doi.org/10.1097/yic.0b013e3282f424c2","is_oa":false,"landing_page_url":"https://doi.org/10.1097/yic.0b013e3282f424c2","pdf_url":null,"source":{"id":"https://openalex.org/S149156103","display_name":"International Clinical Psychopharmacology","issn_l":"0268-1315","issn":["0268-1315","1473-5857"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310318547","host_organization_name":"Wolters Kluwer","host_organization_lineage":["https://openalex.org/P4310318547"],"host_organization_lineage_names":["Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"International Clinical Psychopharmacology","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W1998767099"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5113610099","display_name":"Alan Lenox\u2010Smith","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Alan J. Lenox-Smith","raw_affiliation_strings":["Wyeth UK, Huntercombe Lane South, Slough, UK. lenoxsa@wyeth.com","Wyeth UK, Huntercombe Lane South, Slough, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Wyeth UK, Huntercombe Lane South, Slough, UK. lenoxsa@wyeth.com","institution_ids":[]},{"raw_affiliation_string":"Wyeth UK, Huntercombe Lane South, Slough, UK","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5102710058","display_name":"Qin Li Jiang","orcid":"https://orcid.org/0009-0002-8825-5747","observed_orcids":["https://orcid.org/0009-0002-8825-5747"]},"institutions":[{"id":"https://openalex.org/I4403928396","display_name":"Wyeth","ror":"https://ror.org/035j24j42","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899","https://openalex.org/I4403928396"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Qin Jiang","raw_affiliation_strings":["Wyeth Research, Collegeville, Pennsylvania, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Wyeth Research, Collegeville, Pennsylvania, USA","institution_ids":["https://openalex.org/I4403928396"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5113610099"],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":3.6471,"has_fulltext":false,"cited_by_count":67,"citation_normalized_percentile":{"value":0.91494561,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"23","issue":"3","first_page":"113","last_page":"119"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11071","display_name":"Treatment of Major Depression","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11071","display_name":"Treatment of Major Depression","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10853","display_name":"Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes","score":0.0,"subfield":{"id":"https://openalex.org/subfields/3205","display_name":"Experimental and Cognitive Psychology"},"field":{"id":"https://openalex.org/fields/32","display_name":"Psychology"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T10272","display_name":"Mental Health Treatment and Access","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/venlafaxine-extended-release","display_name":"venlafaxine extended release","score":0.9739999771118164},{"id":"https://openalex.org/keywords/citalopram","display_name":"citalopram","score":1.0},{"id":"https://openalex.org/keywords/treatment-resistant-depression","display_name":"treatment-resistant depression","score":0.7850000262260437},{"id":"https://openalex.org/keywords/major-depressive-disorder","display_name":"major depressive disorder","score":0.9359999895095825},{"id":"https://openalex.org/keywords/antidepressant-switching","display_name":"antidepressant switching","score":0.7739999890327454},{"id":"https://openalex.org/keywords/depression-severity","display_name":"depression severity","score":0.6299999952316284},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.6190000176429749},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.4390000104904175},{"id":"https://openalex.org/keywords/antidepressant-efficacy","display_name":"antidepressant efficacy","score":0.5429999828338623},{"id":"https://openalex.org/keywords/outpatients","display_name":"outpatients","score":0.5170000195503235},{"id":"https://openalex.org/keywords/adverse-drug-reactions","display_name":"adverse drug reactions","score":0.3499999940395355}],"concepts":[{"id":"https://openalex.org/C2777490545","wikidata":"https://www.wikidata.org/wiki/Q409672","display_name":"Citalopram","level":4,"score":0.9496250152587891},{"id":"https://openalex.org/C2776466888","wikidata":"https://www.wikidata.org/wiki/Q898407","display_name":"Venlafaxine","level":4,"score":0.8380120992660522},{"id":"https://openalex.org/C2780092697","wikidata":"https://www.wikidata.org/wiki/Q7455053","display_name":"Serotonin reuptake inhibitor","level":4,"score":0.7003765106201172},{"id":"https://openalex.org/C31487548","wikidata":"https://www.wikidata.org/wiki/Q4859664","display_name":"Reuptake inhibitor","level":4,"score":0.6341364979743958},{"id":"https://openalex.org/C2909532165","wikidata":"https://www.wikidata.org/wiki/Q898407","display_name":"Venlafaxine Hydrochloride","level":5,"score":0.6227641105651855},{"id":"https://openalex.org/C2779583969","wikidata":"https://www.wikidata.org/wiki/Q423757","display_name":"Escitalopram","level":4,"score":0.5100379586219788},{"id":"https://openalex.org/C2780051608","wikidata":"https://www.wikidata.org/wiki/Q42844","display_name":"Major depressive disorder","level":3,"score":0.5044726133346558},{"id":"https://openalex.org/C2777669559","wikidata":"https://www.wikidata.org/wiki/Q407617","display_name":"Sertraline","level":4,"score":0.49901533126831055},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.48062628507614136},{"id":"https://openalex.org/C2776867660","wikidata":"https://www.wikidata.org/wiki/Q1814941","display_name":"Depression (economics)","level":2,"score":0.47399628162384033},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.47317272424697876},{"id":"https://openalex.org/C2776466505","wikidata":"https://www.wikidata.org/wiki/Q385555","display_name":"Hamilton Rating Scale for Depression","level":4,"score":0.4727039337158203},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.4659251868724823},{"id":"https://openalex.org/C2781210005","wikidata":"https://www.wikidata.org/wiki/Q6738337","display_name":"Major depressive episode","level":3,"score":0.43145668506622314},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.4284569025039673},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.42681217193603516},{"id":"https://openalex.org/C42219234","wikidata":"https://www.wikidata.org/wiki/Q131130","display_name":"Anesthesia","level":1,"score":0.3746953010559082},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.3223170340061188},{"id":"https://openalex.org/C2779177272","wikidata":"https://www.wikidata.org/wiki/Q76560","display_name":"Antidepressant","level":3,"score":0.19941124320030212},{"id":"https://openalex.org/C558461103","wikidata":"https://www.wikidata.org/wiki/Q154430","display_name":"Anxiety","level":2,"score":0.16188019514083862},{"id":"https://openalex.org/C2780733359","wikidata":"https://www.wikidata.org/wiki/Q331769","display_name":"Mood","level":2,"score":0.11703711748123169},{"id":"https://openalex.org/C2778709874","wikidata":"https://www.wikidata.org/wiki/Q190875","display_name":"Hydrocortisone","level":2,"score":0.058605700731277466},{"id":"https://openalex.org/C162324750","wikidata":"https://www.wikidata.org/wiki/Q8134","display_name":"Economics","level":0,"score":0.0},{"id":"https://openalex.org/C139719470","wikidata":"https://www.wikidata.org/wiki/Q39680","display_name":"Macroeconomics","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000069470","descriptor_name":"Venlafaxine Hydrochloride","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001315","descriptor_name":"Australia","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003511","descriptor_name":"Cyclohexanols","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D003511","descriptor_name":"Cyclohexanols","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D003511","descriptor_name":"Cyclohexanols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D003692","descriptor_name":"Delayed-Action Preparations","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003863","descriptor_name":"Depression","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D003863","descriptor_name":"Depression","qualifier_ui":"Q000523","qualifier_name":"psychology","is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004351","descriptor_name":"Drug Resistance","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D005060","descriptor_name":"Europe","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011446","descriptor_name":"Prospective Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011569","descriptor_name":"Psychiatric Status Rating Scales","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012720","descriptor_name":"Severity of Illness Index","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015283","descriptor_name":"Citalopram","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D015283","descriptor_name":"Citalopram","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D015283","descriptor_name":"Citalopram","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D017211","descriptor_name":"Treatment Failure","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017367","descriptor_name":"Selective Serotonin Reuptake Inhibitors","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D017367","descriptor_name":"Selective Serotonin Reuptake Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D017367","descriptor_name":"Selective Serotonin Reuptake Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D018687","descriptor_name":"Antidepressive Agents, Second-Generation","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D018687","descriptor_name":"Antidepressive Agents, Second-Generation","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D018687","descriptor_name":"Antidepressive Agents, Second-Generation","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1097/yic.0b013e3282f424c2","doi":"https://doi.org/10.1097/yic.0b013e3282f424c2","is_oa":false,"landing_page_url":"https://doi.org/10.1097/yic.0b013e3282f424c2","pdf_url":null,"source":{"id":"https://openalex.org/S149156103","display_name":"International Clinical Psychopharmacology","issn_l":"0268-1315","issn":["0268-1315","1473-5857"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310318547","host_organization_name":"Wolters Kluwer","host_organization_lineage":["https://openalex.org/P4310318547"],"host_organization_lineage_names":["Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"International Clinical Psychopharmacology","raw_type":"journal-article"},{"id":"pmid:18408525","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/18408525","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"International clinical psychopharmacology","raw_type":"Comparative Study"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":17,"referenced_works":["https://openalex.org/W1531202574","https://openalex.org/W1933790375","https://openalex.org/W1970421748","https://openalex.org/W1974208535","https://openalex.org/W2016218615","https://openalex.org/W2023634568","https://openalex.org/W2085769789","https://openalex.org/W2088359472","https://openalex.org/W2099564543","https://openalex.org/W2114613490","https://openalex.org/W2118826874","https://openalex.org/W2131823335","https://openalex.org/W2137672274","https://openalex.org/W2139170222","https://openalex.org/W2149402043","https://openalex.org/W2155891669","https://openalex.org/W2616500375"],"related_works":["https://openalex.org/W2060513074","https://openalex.org/W1992828484","https://openalex.org/W2071410273","https://openalex.org/W2068083208","https://openalex.org/W1983717552","https://openalex.org/W2378987632","https://openalex.org/W2053349379","https://openalex.org/W1994159840","https://openalex.org/W2005693447","https://openalex.org/W2140787893"],"abstract_inverted_index":{"Findings":[0],"from":[1,468,598],"the":[2,48,80,90,113,162,170,188,216,258,266,270,321,341,366,399,420,424,453,462,469,473,492,565,599],"National":[3],"Institute":[4],"of":[5,19,74,84,92,115,117,144,151,175,269,272,343,349,380,442,506,567,581],"Mental":[6],"Health's":[7],"Sequenced":[8],"Treatment":[9,230,374],"Alternatives":[10],"to":[11,46,58,68,78,104,111,124,205,328,528,561,606],"Relieve":[12],"Depression":[13,194,296],"trial":[14,76],"indicate":[15],"that":[16],"approximately":[17],"50%":[18],"patients":[20,96,201,351,362,390,413,555],"with":[21,35,54,146,402,436,455,591],"major":[22],"depressive":[23],"disorder":[24],"do":[25],"not":[26,99,159,445],"experience":[27,100],"a":[28,36,101,129,182,197,238,276,403,437,456,532,579],"treatment":[29,34,52,91,102,121,267,590],"response":[30,103,560],"after":[31,51],"adequate":[32,148],"first-line":[33],"selective":[37],"serotonin":[38],"reuptake":[39],"inhibitor":[40],"(SSRI).":[41],"This":[42,127],"study":[43],"was":[44,128,235,257,279,428,487,497,574],"designed":[45],"test":[47],"hypothesis":[49],"that,":[50],"failure":[53],"an":[55,105,147,152,529,558,562,592],"SSRI,":[56,70],"switching":[57,67,605],"venlafaxine":[59,85,207,245,353,370,392,415,463,507,519,540,547,572],"extended":[60],"release":[61],"(ER)":[62],"would":[63],"offer":[64],"advantages":[65],"over":[66],"another":[69,607],"citalopram.":[71,524,545],"The":[72,253,291,434,481],"objectives":[73],"this":[75],"were":[77,137,202,244,313,357,363,376,396,500,516,537],"compare":[79],"efficacy":[81,450,553,582],"and":[82,87,110,157,172,180,234,289,306,324,360,382,388,411,504,509,521,542,549],"safety":[83],"ER":[86,208,246,464,508,520,541,548,573],"citalopram":[88,109,156,212,250,470,510,550],"in":[89,95,169,365,378,398,419,448,554],"moderate-to-severe":[93],"depression":[94,118,166,273],"who":[97,556,585],"did":[98,444],"SSRI":[106,153,593],"other":[107,154],"than":[108,155,604],"investigate":[112,265],"effects":[114,268],"severity":[116,271],"by":[119,237,502],"categorizing":[120],"groups":[122,375],"according":[123,327],"baseline":[125,282,329,383,404,438,457],"severity.":[126],"12-week,":[130],"double-blind,":[131],"randomized,":[132],"parallel-group,":[133],"multicenter":[134],"study.":[135],"Participants":[136],"adult":[138],"outpatients":[139],"who,":[140],"following":[141,589],"8":[142],"weeks":[143,226,233],"monotherapy":[145],"dosing":[149],"regimen":[150],"had":[158,181,557],"responded,":[160],"met":[161],"diagnostic":[163],"criteria":[164],"for":[165,193,215,281,293,319,518,523,539,544],"as":[167,531],"described":[168],"Diagnostic":[171],"statistical":[173,430],"manual":[174],"mental":[176],"disorders,":[177],"fourth":[178],"edition,":[179],"score":[183,285,407,441,460,479,486,495],">":[184],"or":[185,211,249,287,334,336,409,534],"=20":[186],"on":[187,274,315,472,578],"21-item":[189],"Hamilton":[190],"Rating":[191,297],"Scale":[192,298],"(HAM-D21).":[195],"After":[196],"7-day":[198],"screening":[199],"period,":[200],"randomly":[203,358],"assigned":[204,359],"receive":[206],"75":[209],"mg/day":[210,214,248],"20":[213],"first":[217],"2":[218,225],"weeks.":[219],"Doses":[220],"could":[221],"be":[222],"increased":[223],"every":[224],"through":[227],"week":[228],"6.":[229],"lasted":[231],"12":[232],"followed":[236],"1-week":[239],"tapering":[240],"period.":[241],"Maximum":[242],"dosages":[243],"300":[247],"60":[251],"mg/day.":[252],"primary":[254,322,425,474,533],"end":[255,475,483],"point":[256,476,484],"final":[259],"on-therapy":[260],"total":[261,284,331,348,406,440,459,478,494],"HAM-D21":[262,283,330,405,439,458,477],"score.":[263],"To":[264],"efficacy,":[275],"subgroup":[277,325],"analysis":[278,323,326],"performed":[280],"<":[286,333,408],"=31":[288,335,410],">31.":[290,337],"analyses":[292],"HAM-D21,":[294],"Montgomery-Asberg":[295],"(MADRS),":[299],"Clinical":[300,307],"Global":[301,308],"Impressions":[302,309],"-":[303,310],"Severity":[304],"(CGI-S),":[305],"Improvement":[311],"scores":[312,332],"based":[314],"intent-to-treat":[316],"(ITT)":[317],"population,":[318],"both":[320],"Safety":[338],"assessments":[339],"included":[340,364],"recording":[342],"adverse":[344],"events":[345],"(AEs).":[346],"A":[347],"406":[350],"(200":[352],"ER,":[354,371,393,416],"206":[355],"citalopram)":[356,395,418],"396":[361],"ITT":[367,400],"population":[368,401],"(194":[369],"202":[372],"citalopram).":[373],"similar":[377,552],"terms":[379],"demographics":[381],"psychiatric":[384],"assessments.":[385],"Two":[386],"hundred":[387],"eighty-four":[389],"(137":[391],"147":[394],"present":[397],"112":[412],"(57":[414],"55":[417],">31":[421],"group.":[422],"In":[423,452,564],"analysis,":[426],"there":[427],"no":[429],"difference":[431],"between":[432],"groups.":[433],"group":[435,454,465,471],"20-31":[443],"differ":[446],"significantly":[447,467,575],"any":[449],"parameters.":[451],">31,":[461],"differed":[466],"(P=0.0121).":[480],"secondary":[482,535],"CGI-S":[485],"statistically":[488],"significant":[489],"(P=0.0359),":[490],"although":[491],"MADRS":[493],"(P=0.0930)":[496],"not.":[498],"AEs":[499],"reported":[501],"57.8":[503],"63.4%":[505],"patients,":[511,571],"respectively.":[512],"Overall":[513],"discontinuation":[514],"rates":[515,526],"24.5%":[517],"20.9%":[522],"Discontinuation":[525],"owing":[527],"AE":[530],"reason":[536],"5.5%":[538],"5.3%":[543],"Overall,":[546],"showed":[551],"inadequate":[559],"SSRI.":[563,608],"subset":[566],"more":[568,576,596],"severely":[569,587],"depressed":[570,588],"effective":[577],"number":[580],"measures.":[583],"Patients":[584],"remain":[586],"may":[594],"gain":[595],"benefit":[597],"dual-action":[600],"drug":[601],"venlafaxine,":[602],"rather":[603]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W1998767099","counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":7},{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":3},{"year":2019,"cited_by_count":2},{"year":2018,"cited_by_count":1},{"year":2017,"cited_by_count":7},{"year":2016,"cited_by_count":5},{"year":2015,"cited_by_count":6},{"year":2014,"cited_by_count":5},{"year":2013,"cited_by_count":6},{"year":2012,"cited_by_count":3}],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2016-06-24T00:00:00"}
